Peptide Database (A–Z)
Search and filter every major peptide people are talking about. Each row shows what it is, the evidence level, its US legal status, and whether it’s banned in sport. This is an educational reference, not medical advice — see our disclaimer.
37 of 37 peptides
| Peptide | Category | Evidence | Legal (US) | Sport | Key flag |
|---|---|---|---|---|---|
| 5-Amino-1MQNNMT inhibitor (small molecule, not a peptide)Oral | Longevity | Animal/in-vitro | Gray-market | — | Zero human trials |
| Argireline / MatrixylTopical cosmetic peptidesTopical | Cosmetic / Skin | Preliminary human | Supplement/cosmetic | — | Modest; far weaker than Botox |
| BPC-157Synthetic gastric peptide fragment (VEGF)Injectable / Oral | Healing / Recovery | Preliminary human | Limbo (post-Cat 2) | Banned (S0) | Mostly animal data; theoretical cancer; July 2026 PCAC |
| CagriSemaSemaglutide + cagrilintide (amylin)Injectable | Metabolic / GLP-1 | Strong clinical | Gray-market | — | Investigational; missed its own 25% target |
| CerebrolysinPorcine brain-derived peptide mixtureIV | Nootropic | Preliminary human | Gray-market | — | Cochrane-negative for stroke; porcine |
| CJC-1295GHRH analogInjectable | GH Secretagogue | Preliminary human | Gray-market | Banned (S2) | DAC version 'always-on'; research chemical |
| DihexaAngiotensin-IV synaptogenic compoundOral / Topical | Nootropic | Animal/in-vitro | Limbo (post-Cat 2) | — | Foundational paper RETRACTED 2025 (fabricated data) |
| Epitalon (Epithalon)Pineal tetrapeptide (Khavinson bioregulator)Injectable / Nasal | Longevity | Animal/in-vitro | Limbo (post-Cat 2) | — | Non-replicated Soviet-era data; July 2026 PCAC |
| GHK-Cu (injectable)Copper tripeptide (systemic)Injectable | Healing / Recovery | Animal/in-vitro | Limbo (post-Cat 2) | — | Copper-overload risk |
| GHK-Cu (topical)Copper tripeptide (topical cosmetic)Topical | Cosmetic / Skin | Preliminary human | Supplement/cosmetic | — | Modest; not a retinoid replacement |
| GHRP-2 / GHRP-6First-gen GH-releasing peptidesInjectable | GH Secretagogue | Preliminary human | Gray-market | Banned (S2) | Cortisol/prolactin; intense hunger |
| HexarelinPotent GH-releasing peptideInjectable | GH Secretagogue | Animal/in-vitro | Gray-market | Banned (S2) | Desensitization; raises cortisol |
| HumaninMitochondrial-derived peptideInjectable | Longevity | Animal/in-vitro | Gray-market | — | No interventional trials; centenarian link correlational |
| IpamorelinSelective ghrelin-receptor pentapeptideInjectable | GH Secretagogue | Preliminary human | Gray-market | Banned (S2) | Minimal human efficacy data |
| KisspeptinReproductive hormone peptideInjectable | Sexual Health | Preliminary human | Gray-market | — | Investigational; no consumer product |
| KPValpha-MSH-derived anti-inflammatory tripeptideOral / Topical / Injectable | Healing / Recovery | Animal/in-vitro | Limbo (post-Cat 2) | — | Zero human trials; July 2026 PCAC |
| LarazotideZonulin antagonist ('leaky gut')Oral | Healing / Recovery | Preliminary human | Gray-market | — | Failed pivotal Phase 3 (2022); no product |
| Liraglutide (Saxenda)Older daily GLP-1 (now generic)Injectable | Metabolic / GLP-1 | FDA-approved | FDA-approved Rx | — | Weaker than newer agents |
| LL-37 (Cathelicidin)Human antimicrobial/immune peptideInjectable / Topical | Immune | Animal/in-vitro | Limbo (post-Cat 2) | — | Drives rosacea/psoriasis/lupus autoimmunity |
| Melanotan IINon-selective alpha-MSH analogInjectable / Nasal | Sexual Health | Anecdotal | Illegal/restricted | — | FDA/TGA warnings: priapism, melanoma |
| MK-677 / IbutamorenOral ghrelin mimetic (non-peptide)Oral | GH Secretagogue | Preliminary human | Gray-market | Banned (S2) | Insulin resistance, edema; CHF signal in elderly |
| NAD+ / NMN / NRNAD+ coenzyme + precursorsOral / IV | Longevity | Preliminary human | Supplement/cosmetic | — | No proven function benefit (2025 meta) |
| Orforglipron (Foundayo)First oral small-molecule GLP-1 (Apr 2026)Oral | Metabolic / GLP-1 | FDA-approved | FDA-approved Rx | — | Newest; thyroid boxed warning |
| P21 / P021CNTF-derived neurogenic peptideInjectable / Oral | Nootropic | Animal/in-vitro | Gray-market | — | Entirely preclinical |
| PT-141 / Bremelanotide (Vyleesi)Melanocortin MC4R agonist (HSDD)Injectable | Sexual Health | FDA-approved | FDA-approved Rx | — | Nausea, BP rise; CVD contraindication |
| RetatrutideTriple agonist (GLP-1/GIP/glucagon)Injectable | Metabolic / GLP-1 | Strong clinical | Gray-market | — | NOT approved (Phase 3, ~28% weight loss); sold 'research only' |
| SelankTuftsin-derived anxiolytic peptideNasal | Nootropic | Preliminary human | Gray-market | — | Russia-only validation; no long-term safety |
| Semaglutide (Ozempic/Wegovy)GLP-1 receptor agonistInjectable / Oral | Metabolic / GLP-1 | FDA-approved | FDA-approved Rx | — | GI effects, muscle loss, thyroid boxed warning |
| SemaxACTH(4-10)-derived heptapeptideNasal | Nootropic | Preliminary human | Limbo (post-Cat 2) | — | Russia-only evidence; July 2026 PCAC |
| SermorelinGHRH analogInjectable | GH Secretagogue | Preliminary human | Compoundable | Banned (S2) | Weak adult efficacy; compounded-only |
| SS-31 / Elamipretide (Forzinity)Mitochondria-targeting tetrapeptideInjectable | Longevity | FDA-approved | FDA-approved Rx | — | Barth syndrome ONLY; no anti-aging use |
| SurvodutideGLP-1/glucagon dual agonistInjectable | Metabolic / GLP-1 | Strong clinical | Gray-market | — | Investigational; MASH angle |
| TB-500 (Thymosin beta-4)Thymosin beta-4 fragmentInjectable | Healing / Recovery | Animal/in-vitro | Limbo (post-Cat 2) | Banned (S2) | Zero human trials; July 2026 PCAC |
| Tesamorelin (Egrifta)GHRH analog (HIV lipodystrophy)Injectable | GH Secretagogue | FDA-approved | FDA-approved Rx | Banned (S2) | Off-label anti-aging unproven |
| ThymalinThymic-peptide bioregulatorInjectable | Longevity | Animal/in-vitro | Gray-market | — | Unreplicated mortality claim |
| Thymosin alpha-1 (Zadaxin)Thymic immunomodulator (approved abroad, not US)Injectable | Immune | Preliminary human | Gray-market | — | Largest sepsis RCT negative; US use off-label |
| Tirzepatide (Mounjaro/Zepbound)Dual GIP/GLP-1 agonistInjectable | Metabolic / GLP-1 | FDA-approved | FDA-approved Rx | — | Class GI risks; beats semaglutide head-to-head |
Educational reference compiled November 2026. Legal status is volatile — verify before acting. Not medical advice.